Teclistamab

Plus, we do have other CAR T's that are coming like anita cell, which we may get approved by the end of the year, that appear to have lower rates of delayed neurotoxicity, potentially as low as zero.

zero.So Amrita, you, in your talk, got into, uh, the, uh, Majestic 3 study, uh, you know, uh, looking at, uh, Teclistamab, uh, with, uh, Dara, a big, you know...

ChatGPT said it was the paper of the year incidentally, and I asked ChatGPT and myeloma, and I think everybody kinda agrees with that.

Uh, but you, uh, in your talk, you were con-contrasting the data between, uh, Majestic 3 and Cartitude 4, and this is kinda interesting there in terms of maybe what should come first.